

ASX Release

SUDA INVITED TO NORTHERN AUSTRALIA INVESTMENT FORUM ON TROPICAL DISEASES

PERTH, AUSTRALIA – 3 November 2015: SUDA LTD (ASX: SUD), a leader in oro-mucosal drug delivery, today announces that Mr. Stephen Carter, Chief Executive Officer and Managing Director, has been invited by Hon. Andrew Robb, Minister for Trade and Investment, to attend the Northern Australia Investment Forum, being held in Darwin, Australia from 8 to 10 November 2015.

The Forum is a high-level, invitation-only event. The Minister has invited senior executives from leading international companies and global health philanthropies who are interested to understand better the diversity and scale of Australian research into tropical diseases. Mr. Carter has been invited to promote investment opportunities regarding SUDA's novel anti-malarial sublingual spray, ArTiMist™.

Confirmed attendees include philanthropic groups such as Medicines for Malaria Venture, Wellcome Trust and Drugs for Neglected Disease initiative. In addition, the Forum will be attended by most of the major pharmaceutical companies that have existing interests in developing anti-malarial treatments.

SUDA's Mr. Carter commented: "I am honoured to have been invited to this exclusive event to discuss tropical medicine. The invitation itself is evidence of the interest from the anti-malarial community in our novel sublingual spray, ArTiMist™. The Northern Australia Investment Forum will provide an opportunity for us to continue our dialogue with key executives from the pharmaceutical industry and philanthropic groups with regard to partnering and funding ArTiMist™."



Further information:
STEPHEN CARTER
CHIEF EXECUTIVE OFFICER / MANAGING DIRECTOR
SUDA LTD
Tel: +61 8 6142 5555
sjcarter@sudaltd.com.au

NOTES TO EDITORS:

About SUDA LTD

SUDA LTD (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using novel formulations of existing off-patent pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (ie: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist[®], a first-in-class oral spray of zolpidem for insomnia. ZolpiMist[®] is marketed in the USA and SUDA has rights to the product outside of the Americas and South Africa. SUDA's most advanced development-stage product, ArTiMist[™], is a novel sublingual malaria treatment for children. In a Phase III trial, ArTiMist[™] was shown to be superior to intravenous quinine. Other products in development include oral sprays for the treatment of migraine headache, chemotherapy-induced nausea and vomiting, erectile dysfunction and pre-procedural anxiety. For more information, visit www.sudaltd.com.au